Samsara BioCapital | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Samsara BioCapital/Activity

Samsara BioCapital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

4 investments· OCT 2025 – JUN 2026Show all

Investment

Participated in Nura Bio's $73.8M Series B, led by The Column Group, to advance SARM1 inhibitors for ALS and other neurodegenerative diseases.

Nura Bio

Nura Bio Samsara BioCapital

globenewswire.comJUN 22, 2026

JUN 22, 2026

Investment

Joined EpiBiologics' $107M Series B, co-led by GV and J&J Innovation, to advance bispecific antibody protein degraders in oncology and immunology.

EpiBiologics

EpiBiologics Samsara BioCapital

businesswire.comJAN 8, 2026

JAN 8, 2026

Investment

Founding investor in Link Cell Therapies' $60M Series A launch, led by Johnson & Johnson Innovation, backing logic-gated CAR-T therapies.

Link Cell Therapies

Link Cell Therapies Samsara BioCapital

prnewswire.comDEC 15, 2025

DEC 15, 2025

Investment

Led Excellergy's $70M Series A alongside Red Tree Venture Capital and Decheng Capital, backing a new class of allergy therapeutics (ECRIs).

Excellergy

Excellergy Samsara BioCapital

globenewswire.comOCT 13, 2025

OCT 13, 2025

Milestone

Portfolio company Respira Therapeutics entered an option agreement granting Gossamer Bio the right to acquire it and its lead pulmonary hypertension candidate, RT234.

Respira Therapeutics

Gossamer Bio Respira Therapeutics Samsara BioCapital

prnewswire.comSEP 25, 2025

SEP 25, 2025

Investment

Co-led Alpheus Medical's $52M Series B with HealthQuest Capital to advance an ultrasound-activated glioblastoma therapy.

Alpheus Medical

Alpheus Medical Samsara BioCapital

prnewswire.comMAY 15, 2025

MAY 15, 2025